At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Nasal Glucagondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating Nasal Glucagon for Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant. The study is open to adults with type 1 or type 2 diabetes and will last about 50 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
CollaboratorsLocemia Solutions ULC
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
Primary CompletionApr 2015
First PostedJun 2016
TodayJul 2026
First PostedJun 21, 2016
Enrollment StartJan 1, 2015
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.0 years ago
Interventions
Nasal Glucagondrug
Administered intranasally.